Characterization and treatment of gemcitabine‐ and cisplatin‐resistant bladder cancer cells with a pan‐RAS inhibitor

Combination chemotherapy with gemcitabine and cisplatin (GC) is recommended as the primary treatment for advanced bladder cancer (BC). However, the benefits of this approach are limited owing to the acquisition of drug resistance. Here, we found that gemcitabine‐resistant and cisplatin‐resistant BCs...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshino, Hirofumi, Yokoyama, Seiya, Tamai, Motoki, Okamura, Shunsuke, Iizasa, Sayaka, Sakaguchi, Takashi, Osako, Yoichi, Inoguchi, Satoru, Matsushita, Ryosuke, Yamada, Yasutoshi, Nakagawa, Masayuki, Tatarano, Shuichi, Tanimoto, Akihide, Enokida, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240337/
https://www.ncbi.nlm.nih.gov/pubmed/37079001
http://dx.doi.org/10.1002/2211-5463.13616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240337/
https://www.ncbi.nlm.nih.gov/pubmed/37079001
http://dx.doi.org/10.1002/2211-5463.13616

Ejemplares similares